Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab to prevent leukemic progression in CCUS
NCT05641831Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canakinumab in clonal cytopenia of undetermined significance (CCUS). Started Feb 2023; status: recruiting.
02
Drugs
canakinumab
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT05641831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641831.